Another DPP1 inhibitor, BI 1291583, showed generally positive results and an acceptable safety profile in phase 1 studies in healthy volunteers, supporting the initiation of a phase 2 trial in patients with bronchiectasis (AirleafTM; NCT05238675) (204, 205). Here, CTSC is linked to bronchiectasis.